Global pharmaceutical company, Strides Arcolab is mulling to part ways with its injectable medicines unit called Agila Specialties, which might be valued at more than Stride's current market value of $800 million, as mentioned in few media reports. Company’s Agila unit manufactures injectable medicines. The unit so far has a decent track record of winning approvals for its new products, it has supply deals with GlaxoSmithKline and Novartis.
Recently, Strides Arcolab’s wholly owned subsidiary Onco Therapies had received final ANDA approval for Oxaliplatin Injection 50mg/10mL and 100mg/20mL. The company had received tentative approval from USFDA in November 2011 based on a Para III filing. This approval was later converted to a Para IV filing based on which USFDA has now granted final approval.
Strides Arcolab is a global pharmaceutical company headquartered in Bangalore, India that develops and manufactures wide range of IP-lead niche pharmaceutical products with an emphasis on sterile injectables.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1531.05 |
Dr. Reddys Lab | 6428.05 |
Cipla | 1482.30 |
Zydus Lifesciences | 1093.45 |
Lupin | 1637.60 |
View more.. |